This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Sugen, SU-11248, SU011248, sunitinib malate
Description: Sutent is an oral medication with anti-tumor and anti-angiogenic activity. As a cancer therapeutic, Sutent blocks the molecular signals generated by certain tyrosine kinases: PDGFR, VEGFR, KIT, and FLT3. Signals from these tyrosine kinases promote the development and sustain the growth of some cancers.
Deal Structure: Pfizer received Sutent from its acquisition of Pharmacia (Pharmacia had previously acquired the biotech company known as SUGEN).
Additional information available to subscribers only: